Alimta

...Investigational Targeted Therapy May Offer Progress for Non-Hodgkin's Lymphoma Patients: Financial News - Yahoo!

Finance Yahoo!

My Yahoo!

Mail Welcome, Guest [Sign Out, My Account] Finance Home - Help Welcome [Sign In] To track stocks & more, Register Financial NewsEnter symbol(s) BasicPerformanceReal-time MktDetailedChartResearchOptionsOrder Book Symbol Lookup Press ReleaseSource: Eli Lilly and Company Investigational Targeted Therapy May Offer Progress for Non-Hodgkin's Lymphoma PatientsSaturday December 10, 9:15 am ET INDIANAPOLIS, Dec.

10 /PRNewswire-FirstCall/ - Data presented today offer evidence that an investigational targeted therapy may be useful in treating patients with the most common form of non-Hodgkin's lymphoma (NHL).

The five-year survival rate of U.S.

patients with NHL is only 59 percent with standard therapies, according to the Lymphoma Research Foundation.

Diffuse large B-cell lymphoma (DLBCL) is the most frequent form of NHL (1).

Conventional therapies improve outcomes for some patients, but new treatment options are always needed.Phase II data presented today at the American Society of Hematology (ASH) 47th Annual Meeting and Exposition in Atlanta, Georgia, showed enzastaurin HCl, an investigational compound from Lilly Oncology, slowed the progression of DLBCL in several patients pretreated with chemotherapy."The use of enzastaurin in relapsed diffuse large B-cell lymphoma is important for two reasons," said Margaret A.

Shipp, M.D.

director of...

Read more...